Atlas Trials

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Clinical trial NCT06109311 · COMPLETED

Trial details

NCT number
NCT06109311
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 Diabetes
Start date
2023-11-10
Primary completion
2025-09-15
Enrollment
546

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.